In July 2024, the US FDA approved KISUNLA (donanemab-azbt ... clinical decline and significant slowing of entorhinal cortex atrophy in non-carriers of the ApoE-4 allele with mild cognitive ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...

Preserving levels of brain glucose metabolism can both slow cognitive decline and reduces the risk of conversion to dementia.

They also demonstrated brain atrophy—that is, shrinkage of the cerebral cortex in the frontal lobes. The mechanisms by which kidney disease is associated with cognitive impairment and ...

While the two factors contributed additively to longitudinal cognitive decline and brain atrophy, the study found no evidence of a synergistic relationship between CeVD and p-tau181, suggesting ...

Donanemab has been hailed 'a new hope' in the ... About 40 per cent of patients who are treated with this class of drugs develop brain brain swelling and bleeding,' he said.

But until recently, we haven’t had any therapeutics to target the root cause of geographic atrophy, an advanced ... And just like we can’t replace brain cells if they’re lost, retinal ...

A recent study mapped the maternal brain from preconception through the crucial two years ... [+] postpartum, illuminating how the brain reshapes itself during this pivotal life stage.